Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2021.04.024 http://scihub22266oqcxt.onion/10.1016/j.drudis.2021.04.024 33932595!8081580!33932595     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2021 ; 26 (6): 1337-1339 Nephropedia Template TP {{tp|p=33932595|t=2021. Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic |pdf=|usr=}}{{33932595}} gab.com Text Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33932595 #FOAvip Oncology is the frontline of drug development. The current pharmaceutical pipeline is disproportional focused on oncology, where about 1/3 of all phases of development is in this therapeutic area. The emphasis brings about substantial breakthroughs and has made positive impact on the quality of life. However, oncology remains a threat to human existence. To facilitate this process, a comprehensive list of novel/first molecularly targeted oncology drug approvals by the FDA from 2017 to 2020 is assessed. Here, we focus on molecularly targeted oncology drugs and not cytotoxic ones, although the latter remain important. To achieve this purpose, besides their sponsors, years of approval, drug classes, and cancer indications, clinical significance is included. The results show that approved molecularly targeted drugs span across diverse classes, including small molecule receptor inhibitors, and biologics such as monoclonal antibodies, antibody-drug conjugates, check-point inhibitors (i.e., PD1, PDL1, CTLA4) and CAR-T cell therapies. Although complete cure of cancer remains limited, we have made substantial inroads and more is yet to come. Moreover, many of these new knowledge can be extrapolated to other therapeutic areas, especially to those of currently unmet medical needs such as in neurology and other chronic diseases. Twit Text FOAVip Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33932595 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33932595 #FOAvip English Wikipedia <ref>{{Cite pmid|33932595}}</ref> Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic #MMPMID33932595 Oo C; Ameer B Drug Discov Today 2021[Jun]; 26 (6): 1337-1339 PMID33932595show ga Oncology is the frontline of drug development. The current pharmaceutical pipeline is disproportional focused on oncology, where about 1/3 of all phases of development is in this therapeutic area. The emphasis brings about substantial breakthroughs and has made positive impact on the quality of life. However, oncology remains a threat to human existence. To facilitate this process, a comprehensive list of novel/first molecularly targeted oncology drug approvals by the FDA from 2017 to 2020 is assessed. Here, we focus on molecularly targeted oncology drugs and not cytotoxic ones, although the latter remain important. To achieve this purpose, besides their sponsors, years of approval, drug classes, and cancer indications, clinical significance is included. The results show that approved molecularly targeted drugs span across diverse classes, including small molecule receptor inhibitors, and biologics such as monoclonal antibodies, antibody-drug conjugates, check-point inhibitors (i.e., PD1, PDL1, CTLA4) and CAR-T cell therapies. Although complete cure of cancer remains limited, we have made substantial inroads and more is yet to come. Moreover, many of these new knowledge can be extrapolated to other therapeutic areas, especially to those of currently unmet medical needs such as in neurology and other chronic diseases. |*Drug Development/organization & administration/trends[MESH] |*Medical Oncology/methods/trends[MESH] |Antineoplastic Agents, Immunological/*pharmacology[MESH] |Antineoplastic Agents/pharmacology[MESH] |COVID-19/*epidemiology[MESH] |Drug Approval[MESH] |Humans[MESH] |Immune Checkpoint Inhibitors/*pharmacology[MESH] |Immunoconjugates/*pharmacology[MESH] |Molecular Targeted Therapy/methods[MESH] |Neoplasms/*drug therapy[MESH] |SARS-CoV-2[MESH]Revamping the ever-changing landscape of drug development processes in(epmc).pdf DeepDyve Pubget Overpricing